This week’s aspergillosis research highlights evolving management of life-threatening haemoptysis in Chronic Pulmonary Aspergillosis (CPA), new insights into antifungal resistance mechanisms, and continued evidence linking post-tuberculosis lung disease with CPA risk. Notably, species beyond Aspergillus fumigatus — including Aspergillus flavus and Aspergillus udagawae — feature prominently, reinforcing the importance of accurate species identification and susceptibility testing in complex or refractory disease.
Weekly Aspergillosis Literature Update
9–15 February 2026
1️⃣ Clinical Complications & Interventional Management
Refractory Massive Haemoptysis in Chronic Pulmonary Aspergillosis
Superselective Pulmonary Artery Embolization for Refractory Massive Hemoptysis Post-Bronchial Artery Embolization: A Bail-Out Measure
Cardiovasc Intervent Radiol (Feb 15, 2026)
🔗 https://pubmed.ncbi.nlm.nih.gov/41692834/
Focus: Advanced haemoptysis management in Chronic Pulmonary Aspergillosis (CPA)
-
6 of 7 patients had CPA
-
All had failed prior bronchial artery embolization (BAE)
-
Pulmonary artery embolization used as salvage therapy
Why this matters:
Suggests a potential pathway for CPA patients with persistent life-threatening bleeding when conventional embolization fails.
2️⃣ Antifungal Resistance & Drug Sensitivity Mechanisms
Novel Caspofungin Resistance in Aspergillus flavus
Ubiquinone-based gene mutation and protein compactness of CoQ5 may contribute to a novel caspofungin resistance mode in Aspergillus flavus
Diagn Microbiol Infect Dis (Feb 9, 2026)
🔗 https://pubmed.ncbi.nlm.nih.gov/41690241/
Focus: Echinocandin resistance biology
-
Suggests mitochondrial/ubiquinone-linked mechanism
-
Moves beyond classical cell wall mutation models
-
Highlights increasing importance of non-fumigatus species
Why this matters:
Resistance biology is becoming more complex — molecular surveillance may need to expand.
Long Non-Coding RNAs and Antifungal Sensitivity
Genome-wide discovery and phenotyping of non-coding transcripts in A. fumigatus reveals lncRNAs with a role in antifungal drug sensitivity
Nat Commun (Feb 11, 2026)
🔗 https://pubmed.ncbi.nlm.nih.gov/41673015/
Focus: Regulatory genomics in antifungal response
-
Identifies long non-coding RNAs influencing drug sensitivity
-
Suggests new regulatory layers in antifungal resistance
-
Opens potential future therapeutic targets
Why this matters:
Signals a shift from single-gene resistance thinking toward systems-level regulation.
3️⃣ Species-Specific Virulence & Emerging Pathogens
Virulence of Aspergillus flavus and Relatives
Virulence of Aspergillus flavus and relatives using the Galleria mellonella model
Virulence (Epub Feb 13, 2026)
🔗 https://pubmed.ncbi.nlm.nih.gov/41685886/
Focus: Comparative pathogenicity
-
Demonstrates variability in virulence among related species
-
Reinforces need for accurate species identification
Why this matters:
Species differentiation has prognostic and potentially therapeutic implications.
Fatal Dissemination from Cryptic Species
Fatal Fungal Peritonitis Caused by Aspergillus udagawae: An Autopsy Case Report
Intern Med (Feb 10, 2026)
🔗 https://pubmed.ncbi.nlm.nih.gov/41672531/
Focus: Disseminated disease from chronic pulmonary infection
-
Multidrug-resistant A. udagawae
-
Autopsy-confirmed fatal fungal peritonitis
-
Highlights invasive potential of cryptic species
Why this matters:
Supports advanced diagnostics and susceptibility testing in refractory cases.
4️⃣ Structural Lung Disease & Secondary Aspergillosis
CPA Following Cavities and Prednisolone
Chronic pulmonary aspergillosis as a complication of lung cavities and prednisolone treatment
Ugeskr Laeger (Feb 9, 2026)
🔗 https://pubmed.ncbi.nlm.nih.gov/41685454/
Focus: Steroids + cavitation as CPA risk factors
-
Imaging and microbiology confirmed diagnosis
-
Long-term azole therapy successful
-
IgG normalisation observed
Why this matters:
Reinforces the structural lung disease + corticosteroid risk interaction.
Post-Tuberculosis Lung Disease and CPA
Post-tuberculosis lung disease and pulmonary aspergillosis management: challenges and considerations
Expert Rev Anti Infect Ther (Feb 12, 2026)
🔗 https://pubmed.ncbi.nlm.nih.gov/41674445/
Focus: Global burden interface
-
Post-TB structural damage predisposes to CPA
-
Major diagnostic and management challenges highlighted
Why this matters:
Post-tuberculosis lung disease remains one of the largest global drivers of CPA.
5️⃣ Mixed & Extrapulmonary Presentations
Abdominal Wall Aspergillosis
Letter: Abdominal Wall Aspergillosis
Surg Infect (Feb 12, 2026)
🔗 https://pubmed.ncbi.nlm.nih.gov/41680095/
Focus: Extrapulmonary aspergillosis
-
Uncommon presentation
-
Reinforces need for broad diagnostic awareness
Mixed Tuberculosis and Aspergillus Infection
Milky Tea-Colored Pleural Effusion: Empyema Complicated by Pneumothorax Due to Mixed Infection With Mycobacterium tuberculosis and Aspergillus fumigatus
Am J Case Rep (Feb 10, 2026)
🔗 https://pubmed.ncbi.nlm.nih.gov/41664446/
Focus: Dual infection
-
Structural damage enables mixed infection
-
TB diagnosis does not exclude concurrent aspergillosis
Overall Themes This Week
-
🔴 Haemoptysis management continues to evolve in advanced CPA
-
🧬 Resistance mechanisms are becoming increasingly complex
-
🌍 Post-tuberculosis lung disease remains central to global CPA burden
-
🧫 Species identification is clinically important
-
⚠ Mixed and disseminated infections continue to challenge diagnosis
Latest News posts
News archive